tbuckley/cabot-search huggingface dataset:
Efficacy of the oral mTORC1 inhibitor everolimus in relapsed or refractory indolent lymphoma
Authors: N. Nora Bennani, Betsy R. LaPlant, Stephen M. Ansell, Thomas. M. Habermann, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Joseph P. Colgan, Svetomir N. Markovic, Grzegorz S. Nowakowski, William R. Macon, Craig B. Reeder, Joseph R. Mikhael, Donald W. Northfelt, Irene M. Ghobrial, Thomas E. Witzig
Journal: American Journal of Hematology (2017)

Abstract Relapsed indolent lymphoma often becomes refractory to standard chemoimmunotherapy and requires new therapeutic strategies. Targeting the PI3K/mTOR pathway in several types of lymphoma has shown preclinical and clinical efficacy providing the rationale to test this strategy in the treatment of relapsed/refractory indolent lymphomas. We investigated in a phase II open label clinical trial the efficacy and safety of single agent everolimus, an inhibitor of mTORC1, in patients with relapsed/refractory indolent lymphomas. Eligible patients received oral everolimus 10 mg daily on a 28 day‐cycle schedule. The primary endpoint was to evaluate the overall response rate (ORR) and safety of single‐agent everolimus in this patient population. Fifty‐five patients with indolent lymphoma were accrued. The median age was 67 years (range: 33‐85) with a median of five prior therapies (range: 1‐10). The ORR was 35% (19/55; 95% CI: 24‐48%), with complete response unconfirmed in 4% (2/55), and partial response in 31% (17/55). The ORR was 61% (14/23) in the patients with FL. The median time to response was 2.3 months (range: 1.4‐14.1), median duration of response of 11.5 months (95%‐CI: 5.7‐30.4), and a median progression‐free survival of 7.2 months (95%‐CI: 5.5‐12.5). The most common toxicity was hematologic with grades 3‐4 anemia, neutropenia, and thrombocytopenia documented in 15% (8/55), 22% (12/55), and 33% (18/55), respectively. There were no cases of febrile neutropenia, and eight patients discontinued therapy because of adverse events. Everolimus monotherapy is a valid therapeutic option in the relapsed and/or refractory indolent non‐Hodgkin lymphoma patients and is well tolerated.
Frequency of potentially actionable genetic alterations in EORTC SPECTAcolor
Authors: G. Folprecht, P. Beer, R. Salazar, A. Roth, D. Aust, R. Salgado, P. Laurent-Puig, J. Tabernero, D. Arnold, A. Stein, V. Golfinopoulos, A. Atasoy, E. Szepessy, M.P. Ducreux, T. Gorlia, S. Tejpar
Journal: Annals of Oncology (2016)
Final analysis of irinotecan (CPT-11) and capecitabine (X) as first-line treatment of locally advanced (LA) or metastatic colorectal cancer (MCRC)
Authors: A. Muñoz, A. Salud, V. Alonso, P. Escudero, J. J. Sanz, C. Martín, F. Rivera, A. Yubero, C. García-Girón, G. López-Vivanco
Journal: Journal of Clinical Oncology (2004)

3610
Role of induction chemotherapy in the multimodal management of locally advanced epithelial sinonasal cancer: a single center experience
Authors: R. Granata, P. Bossi, C. Bergamini, S. Alfieri, C. Resteghini, D. Galbiati, E. Orlandi, N.A. Iacovelli, C. Fallai, M. Guzzo, G. Infante, L. Locati, R. Miceli, L. Mariani, L. Licitra
Journal: Annals of Oncology (2016)
Matched Unrelated Donor Stem Cell Transplantation for Patients with Diffuse Large Cell B Cell Lymphoma: A Retrospective Analysis of 118 Patients Registered through the European Group for Blood and Marrow Transplantation (EBMT).
Authors: Irit Avivi, Carme Canals, Goli Taghipour, Dietger Niederwieser, Lothar Kanz, Gerhard Ehninger, Jurgen Finke, Hildegard T. Greinix, Arnon Nagler, Jean Paul Vernant, Sebastien Maury, Marco Bregni, Werner Linkesch, Rainer Schwerdtfeger, Anna Sureda
Journal: Blood (2006)
Profile of the colorectal (CRC) cancer (Ca) patients (PTS) in Turkey: A cross-sectional disease registry study—A Turkish Oncology Group trial.
Authors: N. Aykan, G. Demir, R. Disci, S. Yalcin, N. S. Turhal, M. Ozdogan, M. Ozkan, A. Yaren, C. Camci, H. Akbulut
Journal: Journal of Clinical Oncology (2011)

394 Background: CRC Ca is one of the most common Ca worldwide. This study was designed to determine the profile of recently diagnosed CRC Ca pts in Turkey. Methods: In this national, multicenter cross-sectional disease registry study, data for 968 pts diagnosed CRC Ca were analyzed. This non-interventional study was supported by sanofi-aventis. Results: From October 2008 to October 2009, 662 colon (68%), 306 rectum (32%) Ca pts were registered from 21 centers in 7 geographic regions of Turkey. Characteristics are as follows. Male 61%, mean age was 60±12 for colon and 57±13 for rectum Ca. The ratio of colon and rectum Ca were equal in the Black Sea region, colon Ca was higher in the other 5 regions except Eastern Anatolia where the highest percentage of rectum Ca was observed (55% vs 45%). Red meat consumption was significantly high only in Eastern Anatolia (p&lt;0.001). The consumption of alcohol, fruit and vegetables didn't show any difference. The percentage of smoking was slightly higher in the rectum Ca group (21% vs 16%, NS). The CRC family history was a risk factor in 7.4% colon, and in 5.6% rectum Ca pts. Among all pts, 1.5% had familial poliposis and only 0.4% had Lynch syndrome. Hypertension (29%) and diabetes mellitus (15%) were the most frequent concomitant diseases. Mean body mass index was 26 ± 4 in colon and 26 ± 5 in rectum Ca pts. Median time between the onset of symptoms and diagnosis was 3 months (mo) for colon and 4 mo for rectum Ca pts. For 46% of pts this time was longer than 4 mo. The mean weight loss in last 6 mo was slightly higher in colon Ca pts (3.9 vs 3.4 kg). Anemia was more frequent in colon Ca pts (p&lt;0.05). Primary tumor location: sigmoid 37% for colon Ca, distal rectum 61% for rectum Ca. In total, 86% of pts were operated (88% of colon, 80% of rectum Ca). In 26% of pts emergency surgery was performed. AJCC staging at diagnosis: I-7%, II-26%, III-35%, IV-32% in colon and I-14%, II-22%, III-39%, IV:25% in rectum. Conclusions: This study showed that colon Ca was more frequent and most of the cases were operated. Data also revealed that pts were diagnosed at considerably later stages. The role of the consumption of red meat, obesity and smoking should be evaluated in larger trial in the future. [Table: see text]
Effect of blood transfusion on early outcome of liver resection for colorectal hepatic metastases.
Authors: S. Gruttadauria, M. Saint Georges Chaumet, D. Pagano, J. W. Marsh, C. Bartoccelli, B. G. Gridelli
Journal: Journal of Clinical Oncology (2011)

314 Background: The useof intraoperative blood transfusions (IBT) has been associated with worse surgical outcome in patients undergoing liver resection for malignancy. However, detailed analyses are required to define clinical findings impacting short-term outcome in this scenario.The aim of this study is to evaluate whether IBT are associated with a worse short-term outcome of liver resection in patients with colorectal hepatic metastases, and to assess whether certain patient characteristics and/or surgical variables affect the need for IBT. Methods: In a series of 127 consecutive patients who underwent partial liver resection for colorectal metastases, between July 1999 and March 2010, we studied postoperative 90 days surgical outcome relative to IBT, and the effect of a variety of factors, including type of resection, surgical technique used, concomitant colo-rectal resection, non-tumoral hepatic histological findings, site of primary tumor, and comorbidities, on the incidence of IBT. Results: Patients who received IBT during their liver resection were more likely to have a longer postoperative length of stay (p = 0.02), to experience complications (p = 0.0003), and to experience a Clavien Grade IIIa or worse complication (p = 0.003). Furthermore, undergoing a major resection, and the presence of portal fibrosis in the non-tumoral liver were both correlated with an increase in IBT (respectively, p = 0.003 and p = 0.049), while the surgical technique used (Kellyclasia or TissueLink), the presence of steatosis, undergoing a concomitant major colonic or rectal resection, and having a major comorbidity had no effect on the incidence of IBT (p ≥ 0.05). Conclusions: This study confirmed that receiving IBT during partial liver resection for colorectal hepatic metastases is associated with a worse short-term surgical outcome. These clinical findings suggest that although several significant factors (surgical technique chosen, comorbidities present, etc.) do not seem to influence the short-term outcome of surgery, it is important to be aware of the deleterious effects of the type of resection performed and the presence of portal fibrosis on blood loss during partial liver resection. No significant financial relationships to disclose.
Effect of adjuvant chemotherapy on bone resorption marker beta C-telopeptide (B-CTX) in postmenopausal women
Authors: S. M. Ali, J. W. Chapman, L. Demers, L. Shepherd, L. Han, C. Wilson, K. Pritchard, K. Leitzel, M. Pollak, A. Lipton
Journal: Journal of Clinical Oncology (2009)

594 Background: In NCIC CTG MA.14, a randomized trial of tamoxifen versus tamoxifen + octreotide LAR, we found a measure of bone resorption, serum B-CTx, to be significantly associated with bone-only first recurrence. Administration of chemotherapy was permitted, and chemotherapy was a stratification factor (never, concurrent, sequential). It was unclear whether pretrial B-CTx serum levels would be affected by prior administration of chemotherapy, and whether timing of chemotherapy was associated with who had bone only, or bone and other site relapse. Methods: Serum B-CTx concentration (Serum CrossLaps Nordic Biosciences, Copenhagen, DN) was determined pretrial therapy in 621 of 667 primary breast cancer patients on MA.14. We tested for differences in continuous B-CTx levels in those who had assessment before (any) chemotherapy (included those who had none) versus those who were assessed after chemotherapy with an ANOVA test. We also used exact Fisher tests to examine whether there was an association between timing of (any) chemotherapy and 1) B-CTx values in upper 2.5% range for healthy pre-menopausal women; 2) bone only recurrence; and 3) concurrent bone and other relapse. Results: Serum B-CTx was assessed before (any) chemotherapy on 382/621 (61.5%) of patients, and after chemotherapy on 239/621 (38.5%). There were no significant differences in serum B-CTx values (p = 0.27). We found 92/621 (14.8%) of patients had high serum B-CTx levels compared with healthy pre-menopausal women; similar proportions of these women received chemotherapy after B-CTx assessment (p = 0.42). Furthermore, there were no differences in timing of (any) chemotherapy and those who had bone only recurrence (p = 0.48) or bone and other type of relapse (p = 0.76). Conclusions: Chemotherapy in the adjuvant setting had no significant effect on bone resorption marker B-CTX serum levels. No significant financial relationships to disclose.
Risk of Thrombosis with Different Approaches to Central Venous Access During Acquired Asparaginase Related Antithrombin Deficiency in Children with Leukemia.
Authors: Susanna Ranta, Mats Heyman, Kirsi Jahnukainen, Mervi Taskinen, Ulla M. Saarinen-Pihkala, Tony Frisk, Stefan Söderhäll, Pia Petrini, Anne Mäkipernaa
Journal: Blood (2012)
APRIL/B Cell Maturation Antigen (BCMA) Signaling Cascades Promote Human Multiple Myeloma Growth and Mediate Immunosuppression in the Bone Marrow Microenvironment Via IL-10, TGF-b, and PD-L1
Authors: Yu-Tzu Tai, Chirag Acharya, Gang An, Michele Moschetta, Mike Zhong, Xiaoyan Feng, Hans van Eenennaam, Andrea van Elsas, Lugui Qiu, Nikhil C. Munshi, Kenneth C Anderson
Journal: Blood (2015)
Evaluation of the association of HER family members with efficacy of trastuzumab therapy in metastatic breast cancer
Authors: A. Koutras, V. Kotoula, G. Kouvatseas, C. Christodoulou, D. Pectasides, A. Batistatou, M. Bobos, E. Tsolaki, K. Papadopoulou, G. Pentheroudakis, P. Papakostas, S. Pervana, K. Petraki, S. Chrisafi, E. Razis, A. Psyrri, D. Bafaloukos, K.T. Kalogeras, H.P. Kalofonos, G. Fountzilas
Journal: Annals of Oncology (2016)
Quality and Safety in Health Care, Part XXIII
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2017)

The efforts of the Vascular Quality Initiative of the Society for Vascular Surgery and its regional groups, including the Vascular Study Group of New England, have been very helpful in furthering medical knowledge in multiple areas of vascular surgery and hopefully in improving quality and safety. One of the areas focused on has been leg bypass surgery. The American College of Surgeons National Surgical Quality Improvement Program has also provided information relevant to leg bypass surgery quality improvement, but there are differences between this program and that from the Vascular Quality Initiative.
Post-Transplant Immune Suppressive Therapy Is Not Necessary In Related and Unrelated Reduced Intensity Conditioning Stem Cell Transplantation Using Low Dose Alemtuzumab In Vivo T Cell Depletion Combined with Alemtuzumab-Mediated In Vitro T Cell Depletion of the Graft
Authors: P.A. Von Dem Borne, C.J.M. Halkes, C.W.J. Starrenburg, W.A.F. Marijt, J.H.F. Falkenburg
Journal: Blood (2010)
Sexual satisfaction, anxiety, depression and quality of life amoung Turkish gynecological cancer patients
Authors: Y. Yildiz, M. Akyol, A. Alacacioglu, Y. Kucukzeybek, N. Asık, H. Taskaynatan, U. Varol, I. Yildiz, U. Oflazoglu, T. Salman, S.U. Ozaltas, M.O. Tarhan
Journal: Annals of Oncology (2016)
Integrated placebo-controlled safety analysis from clinical studies of telotristat ethyl for the treatment of carcinoid syndrome
Authors: M. Kulke, D. Hörsch, M. Caplin, L. Anthony, E. Bergsland, K. Oberg, S. Welin, R. Warner, C. Lombard Bohas, P.L. Kunz, E. Grande, J.W. Valle, P. Lapuerta, P. Banks, S. Jackson, W. Jiang, T. Biran, M. Pavel
Journal: Annals of Oncology (2016)
ATIM-06. DOES THE OCCURRENCE OF A RASH CORRELATE WITH RESPONSE IN GLIOBLASTOMA PATIENTS TREATED WITH IPILIMUMAB?
Authors: Nicholas Brown, Thomas Carter, Heather Shaw, Diego Ottaviani, Kerry Chester, Paul Mulholland
Journal: Neuro-Oncology (2016)

There is emerging evidence for the use of immune checkpoint inhibitors in glioblastoma. These drugs are associated with significant immune-mediated toxicities including skin rash. There remains no established method of identifying those patients most likely to respond but treatment related adverse events have been associated with improved outcomes with other anti-cancer therapies. 37 patients with glioblastoma were consented for treatment with ipilimumab in combination with bevacizumab, along with G-CSF or GM-CSF. Occurrence of a rash and best radiological responses were analyzed and compared for all patients using Fisher’s exact test. Best radiological response data were available for 35 patients; 14 patients (40%) showed a partial response, 13 patients (37%) showed stable disease and 8 patients (23%) showed disease progression. In total, 10 patients (29%) developed a rash following treatment; 7 patients who had a partial response to treatment, and 3 patients who had either stable disease or disease progression. When compared using Fisher’s exact test, a correlation between radiological response and the occurrence of a rash was observed (p=0.028). Whilst the number of patients included in this analysis is small, a correlation is observed between radiological response and the occurrence of a rash following treatment. Further research is needed to evaluate whether this observation is a true correlation, and if so, whether this can help stratify those patients who will receive the most benefit from continuing therapy with ipilimumab.
Clinical Trial of Rituximab Synchronized with Granulocyte Colony-Stimulating Factor in Standard CHOP Chemotherapy for Previously Untreated Patients with Follicular or Diffuse Large B-Cell Lymphomas.
Authors: Yasutaka Kakinoki, Yasushi Yamamoto, Sachiko Suzuki, Takashi Hukuhara, Junji Tanaka, Masahiro Imamura
Journal: Blood (2004)
Assessment of the association of the VeriStrat test with outcomes in patients (pts) with advanced pancreatic cancer (PC) treated with gemcitabine (G) with or without erlotinib (E) in the NCIC CTG PA.3 phase III trial.
Authors: Daniel John Renouf, Wendy Parulekar, Julia Grigorieva, Dongsheng Tu, Malcolm J. Moore
Journal: Journal of Clinical Oncology (2013)

4061 Background: VeriStrat is a mass spectrometry based assay performed on serum or plasma that has been shown to be prognostic in several tumor types, and may predict differential drug benefit in several settings. We investigated the association of VeriStrat with outcomes in the NCIC CTG PA.3 randomized phase III trial of G and E vs. G and placebo (P) in pts with advanced PC. Methods: Pre-treatment plasma samples were available for 499/569 (87.7%) enrolled pts. VeriStrat testing was performed in a CLIA-certified laboratory; pts were classified as either Good, Poor, or indeterminate. The relationship between VeriStrat results and overall survival (OS) and progression free survival (PFS) was assessed by Kaplan-Meier curves and log-rank test in univariate analysis and Cox model adjusting for gender, age [&gt;60 vs. ≤60], race [Caucasian vs. other], ECOG [0-1 vs. 2], and pain intensity at baseline [≤20 vs. &gt;20] in multivariate analysis. The predictive effect was assessed by interaction test. All statistical analyses were performed by the NCIC CTG. Results: Of the 499 samples, 11 were hemolyzed and 4 had acquisition failures. VeriStrat was performed on 484 samples, 9 failed quality control, 22 had indeterminate results. Of the remaining 452, 353 (78%) were classified as Good and 99 (22%) as Poor. In the G and P arm, median OS was 7.16 months (ms) for VeriStrat Good vs. 3.78ms for VeriStrat Poor (p&lt;0.0001); Adjusted Hazard Ratio (AHR) 0.59 (0.43-0.82), p=0.002. In the G and E arm, median OS was 7.33ms for VeriStrat Good vs. 4.50ms for VeriStrat Poor p&lt;0.0001; AHR 0.47 (0.32-0.70), p=0.001. A similar relationship was seen for PFS (G and P arm: median PFS 3.91 vs. 2.07ms (p=0.001); AHR 0.67 [0.49-0.92], p=0.01); G and E arm: median PFS 4.24 vs. 2.86ms (p=0.0004); AHR 0.54 [0.37-0.80], p=0.002). Tests of interaction of VeriStrat status and treatment for OS and PFS were not significant: AHR 0.78 (0.48-1.25), p=0.30 and AHR 0.80 (0.50-1.30), p=0.37 respectively. Conclusions: VeriStrat results were significantly associated with OS and PFS for both regimens in this study. VeriStrat was not predictive of benefit from the addition of E to G.
NIMG-37. IMAGING THE EARLY METABOLIC RESPONSE DURING TUMOR-TREATING FIELDS THERAPY IN RECURRENT GLIOBLASTOMA
Authors: Csaba Juhasz, Sandeep Mittal, Varun B Shah, Edit Bosnyak, Geoffrey R Barger
Journal: Neuro-Oncology (2016)

Tumor-treating fields (TTF) therapy is an innovative treatment approach for newly diagnosed and recurrent glioblastoma. In this study we evaluated whether positron emission tomography with alpha[11C]-methyl-L-tryptophan (AMT-PET) would detect early metabolic responses during the first 3 months of TTF therapy. Five patients with MRI-detected recurrent glioblastoma being treated with temozolomide underwent AMT-PET scanning prior to delivery of TTF. Four of the 5 patients had >75% compliance with the device and underwent a repeat PET scan 1.5 to 3 months later. Interval changes of tumoral tryptophan uptake and PET-based tumor volumes (based on a previously defined threshold) were measured and compared to changes in MRI enhancement. Three patients showed an early metabolic response reflected by interval decrease of tumoral tryptophan uptake and PET-based tumor volumes during the follow-up period. Patients #1 and #2 who received TTF therapy in addition to maintenance temozolomide showed a ≥25% decrease of PET-based tumor volumes 1.5 and 3 months later, respectively, followed by a delayed MRI response 2 months after the second PET scan. In the other two patients, TTF therapy was combined with bevacizumab. Patient #3 showed markedly decreased tumoral AMT uptake and reduced PET-based tumor volume, along with stable MRI contrast enhancement after 3 months, which continued for 3 additional months before progression. Patient #4, with a much larger baseline tumor volume than the other three patients, showed an increase in the PET-based tumor volume during a 2-month follow-up. MRI showed a steady increase in the volume of contrast enhancement both during and after the AMT-PET follow-up period. These preliminary data demonstrate an early metabolic response to TTF therapy in 3 out of 4 the patients with recurrent glioblastoma who maintained good compliance with the device. This metabolic response seems to precede a subsequent MRI response.
The Shaving Reaction Is Facilitated through Trogocytosis: Concerted Transfer of Both Rituximab (RTX) and the Membrane Dye PKH26 from B Lymphocytes to Macrophages Is Demonstrable by Flow Cytometry, Fluorescence Microscopy, and High Resolution Digital Imaging in a Flow Cytometric Environment.
Authors: David A. Mack, Paul V. Beum, Margaret A. Lindorfer, Andrew W. Pawluczkowycz, Ronald P. Taylor
Journal: Blood (2006)
Meta-analysis of randomized clinical trials in metastatic castration resistant prostate cancer: Comparison of hypertension, neurological and psychiatric adverse events on enzalutamide and abiraterone acetate plus prednisone treatment
Authors: P. Ruiz Gracia, L. Dearden, L. Antoni, R. Parra Gabilondo, A. Garcia Garcia-Porrero, M. Iznaola
Journal: Annals of Oncology (2016)
IMST-44. LYMPHOPENIA ENHANCES THE EFFICACY OF CAR T CELLS DELIVERED LOCO-REGIONALLY IN THE BRAIN FOR THE TREATMENT OF GLIOBLASTOMA
Authors: Carter M. Suryadevara, Rupen Desai, David J. Snyder, Qi-Jing Li, Peter E. Fecci, Luis Sanchez-Perez, John H. Sampson
Journal: Neuro-Oncology (2016)

Glioblastoma (GBM) remains the most common and deadly primary malignant brain tumor and adoptive T cell immunotherapy using chimeric antigen receptors (CARs) may be a promising approach for treatment of this disease. Although CARs have proven effective for hematological cancers, this platform must be modified for efficacy and optimal translation for GBM. One barrier to achieving this has been poor T cell expansion, survival, and migration to tumor sites in the central nervous system. Loco-regional delivery of T cells directly into the brain may be one way to circumvent variabilities in T cell migration, and alternatively, radiation and chemotherapy-induced lymphopenia can be leveraged to promote T cell expansion and survival in the periphery to increase the number of brain infiltrating T cells. However, these two approaches have never been combined. We conducted studies to determine whether host lymphopenia improves the efficacy of CAR T cells delivered loco-regionally in the brain. Using CARs targeting the tumor-specific mutation, EGFRvIII, we conducted studies against the syngeneic GBM cell line, KR158B-Luc-EGFRvIII. 14 days after engraftment, mice were subjected to 5Gy total body radiation (TBI) or sham, and injected intracranially with CARs. Radiation dramatically enhanced the efficacy of CARs, inducing complete tumor regression and a nearly 100% cure rate. We found this observation to hold true against a second, highly stringent model of GBM using 7-day established tumors derived from the CT2A-EGFRvIII cell line. Radiation-induced lymphopenia significantly improved the frequency of CARs in the brain, and interestingly, antitumor efficacy occurred independently of CAR T cell entry/exit into peripheral blood circulation. Finally, we found that the lymphodepleting effects of temozolomide (TMZ) sufficiently preconditioned hosts for enhanced efficacy against both models of GBM, supporting the translatability of this observation for patients with GBM.
Phase (ph) 3 study of eribulin (ERI) vs dacarbazine (DTIC) in leiomyosarcoma (LMS) and liposarcoma (LPS) patients (pts)
Authors: Patrick Schöffski, Edwin Choy, Axel Le Cesne, Veridiana Camargo, Sebastian Bauer, Sun Young Rha, Jean-Yves Blay, David R D'Adamo, Matthew Guo, Robert G Maki
Journal: Annals of Oncology (2016)
Treatment with mTOR Inhibitor, Everolimus (RAD001) Overcomes Resistance to Imatinib In Ph-Leukemia Quiescent Cells.
Authors: Yachiyo Kuwatsuka, Yosuke Minami, Miho Minami, Ryohei Tanizaki, Hitoshi Kiyoi, Tomoki Naoe
Journal: Blood (2010)